Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

By daniellenierenberg

Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201

Original post:
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

Related Post


categoriaIPS Cell Therapy commentoComments Off on Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022 | dataNovember 6th, 2022

About...

This author published 4773 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024